CLINICAL_TRIALS
trial_result
· 2020-04-13
Clinical Trial Update: Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension [Phase 2]
Summary
Phase 2 dose-finding study of ACT-132577 (Aprocitentan) in essential hypertension completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Idorsia Pharmaceuticals Ltd. | Conditions: Essential Hypertension | Phase 2 | Status: COMPLETED | Results posted: 2020-04-13